Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.0K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Navigating sexual health, fertility, and adult wellness in individuals with Duchenne muscular dystrophy: Current standards of care and future directions.

Journal of neuromuscular diseases·2026
Same author

Development and Validation of a Novel, Disease-Specific, Caregiver-Reported Outcome Measure: The Duchenne Muscular Dystrophy Caregiver Reported-Health Index (DMDCR-HI).

Muscle & nerve·2026
Same author

Human-milk vitamin B-3 (niacin and vitamer) concentrations: secondary analysis of a randomized, placebo-controlled trial of maternal nicotinamide supplementation in rural Tanzania.

The American journal of clinical nutrition·2026
Same author

Transcranial Motor-Evoked Potentials Provide More Reliable Intraoperative Neuromonitoring Than Somatosensory-Evoked Potentials in Charcot-Marie-Tooth Patients Undergoing Periacetabular Osteotomy for Hip Dysplasia.

Journal of the Pediatric Orthopaedic Society of North America·2026
Same author

Two Patients With Juvenile-Onset, Rapidly Progressive Amyotrophic Lateral Sclerosis Associated With an SOD1 Variant (p.Asp125Gly) With Incomplete Penetrance.

Muscle & nerve·2026
Same author

Optimizing Care for Growth and Puberty in Duchenne Muscular Dystrophy: A Survey of Clinical Practice in the OPTIMIZE DMD Consortium.

Muscle & nerve·2026

Related Experiment Video

Updated: Jul 6, 2025

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
09:18

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy

Published on: January 12, 2019

10.4K

The Early Care (0-3 Years) In Duchenne Muscular Dystrophy Meeting Report.

Niki Armstrong1, Susan Apkon2, Kiera N Berggren3

  • 1Parent Project Muscular Dystrophy, Washington, DC, USA.

Journal of Neuromuscular Diseases
|January 8, 2024
PubMed
Summary

Early diagnosis and care for Duchenne muscular dystrophy (DMD) in infants aged 0-3 years are crucial. This meeting highlighted the need for evidence-based guidelines and comprehensive support for families managing DMD.

Keywords:
Duchenne muscular dystrophygenetic carrier screeninggenetic counselinggenetic testingneurodevelopmental disordersneuromuscular diseases –diagnosisnewborn screeningpatient care managementtherapeutics

More Related Videos

Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases
06:52

Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases

Published on: September 29, 2014

53.7K
Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice
08:13

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice

Published on: April 10, 2019

6.1K

Related Experiment Videos

Last Updated: Jul 6, 2025

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
09:18

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy

Published on: January 12, 2019

10.4K
Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases
06:52

Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases

Published on: September 29, 2014

53.7K
Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice
08:13

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice

Published on: April 10, 2019

6.1K

Area of Science:

  • Pediatric Neuromuscular Disorders
  • Genetics and Rare Diseases

Background:

  • Duchenne muscular dystrophy (DMD) diagnosis and care for infants (0-3 years) present unique challenges.
  • Limited evidence-based guidelines exist for early DMD management.
  • Female carriers of DMD also require specific attention and care strategies.

Framework:

  • The meeting convened experts to discuss advancements in DMD diagnosis and care for young children.
  • Key areas included diagnostic delays, ethnic disparities, and newborn screening potential.
  • Discussions covered approved therapies (corticosteroids, exon-skipping) and ongoing clinical trials (ataluren, vamorolone, gene therapy).

Implementation:

  • Emphasis on timely diagnosis and addressing diagnostic disparities.
  • Exploration of early intervention with corticosteroids and safety of exon-skipping drugs.
  • Focus on clinical trials for infants and young boys, including novel gene therapies.

Implications:

  • Need for developing evidence-based guidelines for early DMD care (0-3 years).
  • Importance of comprehensive family support, including information and early intervention services.
  • Call for further research, collaboration, and consensus to improve outcomes for children with DMD and their carriers.